Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723654 · ClinicalTrials.gov registry record
Evaluating Wearable Smart Sensors for Continuous Measurement of Vital Signs in ICU Patients
A clinical trial of Prematurity, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Recruiting
- Registry status
- 500
- Enrollment target
- 2
- Study locations
NCT04723654: Recruiting study of Prematurity, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
NCT04723654 is a study of Prematurity that is actively recruiting participants, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 500 participants, above the 187-participant average among 21 other Prematurity trials with a reported enrollment target (167% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04723654, a study of Prematurity, is actively recruiting participants, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to develop biocompatible wireless electronic devices that will allow continuous, non-invasive hemodynamic and physiology measurements in the ICU.
Primary Outcome
Recorded measurements of BP as compared to the ICU standard of care monitoring, including both arterial line measurements and cuff-based measurements of the arm (mm Hg).
Conditions Studied
Interventions
- DEVICE Wireless Wearable Vital Sign Monitor
Study Locations (2)
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- Northwestern Medicine Prentice Women's Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2026-06-30 |
What NCT04723654 shows while recruiting
NCT04723654 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 187-participant average among 21 other Prematurity trials with a reported enrollment target (167% higher).
The record links to 1 condition, with Prematurity appearing as the primary indexed condition, and to 1 intervention - of which Wireless Wearable Vital Sign Monitor is the first listed.
NCT04723654 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04723654 about?
NCT04723654 is a clinical study titled "Evaluating Wearable Smart Sensors for Continuous Measurement of Vital Signs in ICU Patients". The purpose of this study is to develop biocompatible wireless electronic devices that will allow continuous, non-invasive hemodynamic and physiology measurements in the ICU.
What is the current status of trial NCT04723654?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2018-03-15. Estimated completion is 2026-06-30.
What conditions does trial NCT04723654 study?
This clinical trial studies the following conditions: Prematurity.
What interventions are being tested in trial NCT04723654?
The interventions under investigation include: Wireless Wearable Vital Sign Monitor (DEVICE).
Who is sponsoring clinical trial NCT04723654?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04723654 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prematurity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04723654's enrollment target sits among peer trials
500 3rd of 21 higher than 19 of 21 other Prematurity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prematurity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
RECRUITING · Phase 2
-
The Impact of Music Medicine on Preterm Brain Development and Behavior
RECRUITING · NA
-
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
RECRUITING · NA
-
Nourishing Tomorrow: Role of Medically Tailored Groceries in Addressing Food Insecurity During Pregnancy
RECRUITING · NA
-
Maternal Stress, Milk Composition, and Preterm Neurodevelopment
RECRUITING
-
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI